Search
CX-046684
go.drugbank.com/drugs/DB19414ApprovedCX-046684 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage KP.2.
Sevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] Sevabertinib functions as a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2), also exhibiting activity against epidermal growth factor receptor (EGFR). … Sevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain
Methaqualone
go.drugbank.com/drugs/DB04833ApprovedIllicitWithdrawnIts use peaked in the early 1970s as a hypnotic, sedative, and muscle relaxant commonly used for insomnia. … Methaqualone is a sedative-hypnotic drug that is similar in effect to barbiturates, a general central nervous system depressant.
Docetaxel
go.drugbank.com/drugs/DB01248ApprovedInvestigationalDocetaxel is a complex diterpenoid molecule and a semisynthetic analogue of [paclitaxel]. … [A259676] Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: DOCETAXEL DONG-A, DOCETAXEL PHARMAKI GENERICSDigoxin
go.drugbank.com/drugs/DB00390ApprovedInvestigational[A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. … They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.[A178240]
Categories: BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexLonafarnib
go.drugbank.com/drugs/DB06448ApprovedInvestigational[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an … aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.
Doxercalciferol
go.drugbank.com/drugs/DB06410ApprovedInvestigationalDoxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin … Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients
Genistein
go.drugbank.com/drugs/DB01645InvestigationalAn isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. … It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women [A14417].
Categories: Compounds used in a research, industrial, or household settingStrontium ranelate
go.drugbank.com/drugs/DB09267ApprovedWithdrawnStrontium ranelate, a strontium (II) salt of ranelic acid, is a medication for osteoporosis. … It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in treatment of severe osteoporosis.
Brotizolam
go.drugbank.com/drugs/DB09017ApprovedWithdrawnBrotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 - 7.9 hours). … Brotizolam is a sedative-hypnotic thienodiazepine drug which is a benzodiazepine analog. It demonstrates anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant effects.
International brands: Brotizolam MProducts: BROTIZOLAM DOC GENERICI